美国黑人前列腺癌患者临床试验与精准肿瘤学可及性差异的叙述性综述
该叙述性综述综合2010至2021年定性与定量研究、综述及随机对照试验,探讨美国黑人前列腺癌患者在临床试验和精准肿瘤学可及性方面的差异。黑人患者发病更早、分期更晚、前列腺癌特异性生存更差,原因涉及医疗可及性、肿瘤免疫生物学与基因组学差异、筛查与管理模式不同及研究代表性不足。作者提出多层次干预框架以缩小差异。
要点
- 黑人前列腺癌患者发病更早、分期更晚、特异性生存更差。
- 差异原因涉及医疗可及性、肿瘤免疫生物学与基因组学、筛查与管理模式及研究代表性不足。
- 研究代表性不足可能削弱风险计算器与生物标志物的验证,导致高危人群治疗决策不佳。
核心结论
- 为避免黑人前列腺癌结局的种族差异扩大,需通过多层次变革增加黑人男性在精准肿瘤学和临床试验中的纳入。
研究设计与样本
- 叙述性综述,综合2010至2021年定性与定量研究、综述及随机对照试验,检索PubMed并使用多个关键词单独或组合检索。
主要发现
- 美国黑人前列腺癌患者较白人发病更早、分期更晚、前列腺癌特异性生存更差。
- 潜在原因包括医疗可及性差异、肿瘤免疫生物学与基因组学差异、筛查率与管理模式不同及临床与转化研究代表性不足。
临床怎么用
- 资助少数族裔服务机构作为招募站点,并在资助研究中纳入循证招募方法以增加黑人代表性。
- 增加黑人男性在精准肿瘤学和临床试验中的纳入,以改善风险计算器和生物标志物在高危人群中的验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide commentary on the disparities in access to clinical trials and precision oncology specific to Black men with Prostate Cancer (PCa) in the United States and lend a general framework to aid in closing these gaps. MATERIALS AND METHODS: The ideas, commentaries and data presented in this narrative review were synthesized by utilizing qualitative and quantitative studies, reviews, and randomized control trials performed between 2010 and 2021. We searched PubMed using the key words "Medicaid", "Medicare", "clinical trials", "African Americans", "Black", "underrepresentation", "access", "Prostate Cancer", "minority recruitment", "racial disparities", "disparity", "genomics", "biomarkers", "diagnostic" "prognostic", "validation", "precision medicine", and "precision oncology" to identify important themes, trends and data described in the current review. Keywords were used alone and combination with both "AND" and "OR" terms. RESULTS: Black men with prostate cancer (PCa) in the United States have earlier onset of disease, present with more advanced stages, and worse prostate cancer-specific survival than their White counterparts. Potential causative factors vary from disparities in health care access to differences in tumor immunobiology and genomics along with disparate screening rates, management patterns and underrepresentation in clinical and translational research such as clinical trials and precision oncology. CONCLUSION: To avoid increasing the racial disparity in PCa outcomes for Black men, we must increase inclusion of Black men into precision oncology and clinical trials, using multilevel change. Underrepresentation in clinical and translational research may potentiate poorly validated risk calculators and biomarkers, leading to poor treatment decisions in high-risk populations. Relevant actions include funding to include minority-serving institutions as recruitment sites, and inclusion of evidence based recruitment methods in funded research to increase Black representation in clinical trials and translational research.
引用
- Esdaille AR, Ibilibor C, Holmes A, et al. Access and Representation: A Narrative Review of the Disparities in Access to Clinical Trials and Precision Oncology in Black men with Prostate Cancer. Urology. 2021. PMID: 34582887. doi:10.1016/j.urology.2021.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。